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Summary
Background Patient-reported outcomes (PROs) might detect more toxic eﬀ ects of radiotherapy than do clinician-
reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally 
fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity 
Modulated Radiotherapy in Prostate Cancer (CHHiP) trial.
Methods The CHHiP trial is a randomised, non-inferiority phase 3 trial done in 71 centres, of which 57 UK hospitals 
took part in the QoL substudy. Men with localised prostate cancer who were undergoing radiotherapy were eligible 
for trial entry if they had histologically conﬁ rmed T1b–T3aN0M0 prostate cancer, an estimated risk of seminal vesicle 
involvement less than 30%, prostate-speciﬁ c antigen concentration less than 30 ng/mL, and a WHO performance 
status of 0 or 1. Participants were randomly assigned (1:1:1) to receive a standard fractionation schedule of 74 Gy in 
37 fractions or one of two hypofractionated schedules: 60 Gy in 20 fractions or 57 Gy in 19 fractions. Randomisation 
was done with computer-generated permuted block sizes of six and nine, stratiﬁ ed by centre and National 
Comprehensive Cancer Network (NCCN) risk group. Treatment allocation was not masked. UCLA Prostate Cancer 
Index (UCLA-PCI), including Short Form (SF)-36 and Functional Assessment of Cancer Therapy-Prostate (FACT-P), 
or Expanded Prostate Cancer Index Composite (EPIC) and SF-12 quality-of-life questionnaires were completed at 
baseline, pre-radiotherapy, 10 weeks post-radiotherapy, and 6, 12, 18, and 24 months post-radiotherapy. The CHHiP 
trial completed accrual on June 16, 2011, and the QoL substudy was closed to further recruitment on Nov 1, 2009. 
Analysis was on an intention-to-treat basis. The primary endpoint of the QoL substudy was overall bowel bother and 
comparisons between fractionation groups were done at 24 months post-radiotherapy. The CHHiP trial is registered 
with ISRCTN registry, number ISRCTN97182923.
Findings 2100 participants in the CHHiP trial consented to be included in the QoL substudy: 696 assigned to the 
74 Gy schedule, 698 assigned to the 60 Gy schedule, and 706 assigned to the 57 Gy schedule. Of these individuals, 
1659 (79%) provided data pre-radiotherapy and 1444 (69%) provided data at 24 months after radiotherapy. Median 
follow-up was 50·0 months (IQR 38·4–64·2) on April 9, 2014, which was the most recent follow-up measurement 
of all data collected before the QoL data were analysed in September, 2014. Comparison of 74 Gy in 37 fractions, 
60 Gy in 20 fractions, and 57 Gy in 19 fractions groups at 2 years showed no overall bowel bother in 269 (66%), 
266 (65%), and 282 (65%) men; very small bother in 92 (22%), 91 (22%), and 93 (21%) men; small bother in 
26 (6%), 28 (7%), and 38 (9%) men; moderate bother in 19 (5%), 23 (6%), and 21 (5%) men, and severe bother in 
four (<1%), three (<1%) and three (<1%) men respectively (74 Gy vs 60 Gy, ptrend=0·64, 74 Gy vs 57 Gy, ptrend=0·59). 
We saw no diﬀ erences between treatment groups in change of bowel bother score from baseline or pre-radiotherapy 
to 24 months.
Interpretation The incidence of patient-reported bowel symptoms was low and similar between patients in the 
74 Gy control group and the hypofractionated groups up to 24 months after radiotherapy. If eﬃ  cacy outcomes from 
CHHiP show non-inferiority for hypofractionated treatments, these ﬁ ndings will add to the growing evidence for 
moderately hypofractionated radiotherapy schedules becoming the standard treatment for localised prostate cancer.
Funding Cancer Research UK, Department of Health, and the National Institute for Health Research Cancer Research 
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Introduction
Prostate cancer is the most common cancer in men in the 
UK, with 41 700 patients diagnosed in 2011.1 For patients 
diagnosed with localised disease, external beam 
radiotherapy, radical prostatectomy, and brachytherapy are 
conventional treatments with similar control rates for 
organ-conﬁ ned tumours. Management choices are 
therefore often aﬀ ected by potential treatment-related toxic 
eﬀ ects. Patient-reported outcomes (PROs) detect treatment 
side-eﬀ ects more reliably than do clinician-reported 
measures and might better guide treatment decisions.2,3
The Conventional or Hypofractionated High Dose 
Intensity Modulated Radiotherapy in Prostate Cancer 
(CHHiP) trial (CRUK/06/016) randomly assigned men 
with localised prostate cancer who were undergoing 
radiotherapy to a standard fractionation schedule or to 
one of two hypofractionated regimens. The main aims of 
the trial were to compare the eﬃ  cacy and toxic eﬀ ects of 
conventional and hypofractionated radiotherapy. Quality 
of life (QoL) was assessed in a substudy within the main 
trial, in which we aimed to assess whether PROs diﬀ ered 
between patients receiving conventionally fractionated 
versus hypofractionated radiotherapy up to 24 months 
after radiotherapy.
Methods
Study design and participants
CHHiP was a randomised, non-inferiority phase 3 trial 
done in three seamless stages. Participation in the QoL 
substudy was open to all UK centres participating in the 
main trial. Because it recruited ahead of schedule, the QoL 
substudy closed to accrual before the main trial closed. 
Men older than 16 years who had histologically 
conﬁ rmed T1b–T3aN0M0 prostate cancer and a WHO 
performance status 0 or 1 were eligible for participation. 
Initially, men with a prostate-speciﬁ c antigen (PSA) 
concentration of less than 40 ng/mL and risk of lymph 
node involvement less than 30% were eligible; on 
Aug 1, 2006, these criteria were revised and a PSA 
concentration less than 30 ng/mL and a risk of seminal 
vesicle involvement less than 30% were needed. Patients 
were ineligible if they had T3 tumours and a Gleason 
score of 8 or higher, or a life expectancy of less than 
10 years. Full details of trial design, eligibility, and 
treatment have been reported previously.4
The study was approved by the London Multi-centre 
Research Ethics Committee (04/MRE02/10). It was 
sponsored by the Institute of Cancer Research and was 
done in accordance with the principles of good clinical 
practice. All patients provided written informed 
consent. The Institute of Cancer Research Clinical 
Trials and Statistics Unit (ICR-CTSU; Sutton, UK) 
coordinated the study and carried out central statistical 
data monitoring and all analyses. The trial management 
group was overseen by an independent trial steering 
committee. 
Randomisation and masking
Men were registered in the trial before or after starting 
initial hormone therapy. 4–6 weeks before radiotherapy, 
participants were randomly assigned (1:1:1) to receive a 
standard fractionation (control) or one of two 
hypofractionated schedules. Randomisation was done 
centrally via telephone calls to the ICR-CTSU. Computer-
generated random permuted blocks were used, with 
block sizes of six and nine. Patients were stratiﬁ ed by 
centre and National Comprehensive Cancer Network 
(NCCN) risk group. Neither treatment allocation nor 
Research in context
Evidence before this study
Randomised controlled trials of moderately hypofractionated 
radiotherapy schedules versus conventionally fractionated 
radiotherapy for localised prostate cancer, using both older and 
more modern radiotherapy techniques, have shown 
inconsistent results for both eﬃ  cacy and side-eﬀ ects. These 
studies have not usually included health-related quality of life 
or patient-reported outcomes (PROs), which detect more 
side-eﬀ ects than do clinician-reported outcomes. We searched 
PubMed using the terms “patient-reported outcomes” OR 
“quality of life” AND “hypofractionated” OR 
“hypofractionation” AND “prostate” up to Oct 1, 2002, and 
retrieved eight articles. Of these articles, none reported PROs 
from randomised trials of conventional versus 
hypofractionated radiotherapy.
Added value of this study
To our knowledge, this study is the largest randomised trial of 
moderately hypofractionated versus conventionally 
fractionated radiotherapy using modern radiotherapy 
techniques, and the ﬁ rst to report PROs up to 2 years after 
treatment, showing both early and late developing side-eﬀ ects. 
Other randomised trials that have included PROs and have been 
reported since this study began used older radiotherapy 
techniques, or only included follow-up to 3 months after 
radiotherapy, therefore assessing early rather than late 
treatment eﬀ ects, which are usually dose-limiting.
Implications of all the available evidence
If eﬃ  cacy outcomes from CHHiP show non-inferiority for 
hypofractionated treatments, the absence of any diﬀ erence in 
PROs between trial groups adds to the growing evidence for 
moderately hypofractionated radiotherapy schedules becoming 
the standard treatment for localised prostate cancer. 
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clinical assessment were masked because sham 
radiotherapy was not given.
Procedures
Men with NCCN intermediate-risk or high-risk disease 
received short-course androgen suppression for 
3–6 months before and during radiotherapy; this was 
optional for patients with low-risk disease. Individuals 
assigned to the control group received standard 
radiotherapy with 2 Gy daily fractions (Monday to Friday 
treatment) for 7·4 weeks, to give a total dose of 74 Gy in 
37 fractions. Individuals in the experimental groups 
received hypofractionated treatment with 3 Gy daily 
fractions to a total dose of either 60 Gy in 20 fractions in 
4·0 weeks or 57 Gy in 19 fractions in 3·8 weeks. For the 
hypofractionated schedules, the protocol stated that the 
overall duration of treatment should be at least 28 days 
for the 20-fraction schedule and at least 27 days for the 
19-fraction schedule. This was to avoid undue shortening 
of overall treatment time and, in practice, meant that 
treatment started on a Wednesday to Friday. Forward or 
inverse three-dimensional methods were used to plan 
radiotherapy treatment. Further details of treatment and 
quality assurance have been reported previously.4
Men consenting to participate in the QoL substudy 
were eligible to complete questionnaires at trial entry if 
they had not already started endocrine treatment, to 
minimise the eﬀ ect of toxicity of hormone deprivation on 
QoL at this timepoint. All men were eligible to complete 
further questionnaires pre-radiotherapy, and at 10 weeks 
and 6, 12, 18, and 24 months after the start of radiotherapy. 
From trial entry to 6 months after radiotherapy, 
questionnaires were administered in the clinic, and 
subsequent questionnaires were posted to patients from 
the ICR-CTSU after local veriﬁ cation of their current 
health status. All QoL questionnaires were self-
administered.
During the planning stages of the CHHiP trial, the 
University of California, Los Angeles Prostate Cancer 
Index (UCLA-PCI) was an important QoL instrument 
available for use in patients with localised prostate 
cancer.5 Subsequently it became apparent that this 
instrument needed augmentation to better capture the 
broad range of urinary, bowel, sexual, and hormonal 
symptoms in patients receiving external beam 
radiotherapy or brachytherapy, or undergoing radical 
prostatectomy. Consequently the Expanded Prostate 
Cancer Index Composite (EPIC) QoL instrument was 
developed that had item content that better represented 
typical symptoms after radiotherapy.6 To maximise the 
sensitivity of the PROs, the QoL instruments were 
updated during the trial to include the EPIC instrument. 
Therefore from trial initiation to early 2009, the 
UCLA-PCI, including the Short Form 36 (SF-36) and 
Functional Assessment of Cancer Therapy-Prostate 
(FACT-P) QoL instruments were used.7 Following a 
protocol amendment on March 12, 2009, the EPIC and 
Short Form 12 (SF-12) QoL instruments replaced UCLA-
PCI, SF-36, and FACT-P, although some old 
questionnaires were received back from participants 
after this date.8 EPIC-50 was used for bowel and urinary 
domains and EPIC-26 for sexual and hormonal domains.9
UCLA-PCI consists of 20 items organised into six 
domains, including bowel function (four items), bowel 
bother (one item), urinary function (ﬁ ve items), urinary 
bother (one item), sexual function (eight items), and 
sexual bother (one item). EPIC-50 includes a bowel 
function domain (seven items) and a bowel bother 
domain (seven items), which together form the bowel 
summary domain, and a urinary function domain (ﬁ ve 
items) and a urinary bother domain (seven items), 
which together form a urinary summary domain. 
EPIC-26 includes a sexual function domain (ﬁ ve items) 
and a sexual bother domain (one item), which are 
combined to form a sexual summary domain; there is 
also a hormonal domain (ﬁ ve items). Items in the 
UCLA-PCI and EPIC QoL instruments diﬀ ered: for 
example, the EPIC bowel function domain included 
rectal bleeding, faecal incontinence, and daily bowel 
movements, which were absent from UCLA-PCI, 
whereas bowel distress was represented in the 
UCLA-PCI bowel function domain and absent from 
EPIC-50. Additionally, haematuria and dysuria were 
represented in the EPIC urinary function domain, but 
absent from UCLA-PCI. All QoL instrument scores 
range from 0 to 100 and a higher score represents better 
QoL.
Health-related QoL was assessed using the FACT-P 
and SF-36 instruments (with UCLA-PCI) or the SF-12 
instrument (with EPIC). FACT-P consists of physical, 
social, functional, and emotional wellbeing domains; 
each domain has seven items, and scores per domain 
range from 0 to 28, except for emotional wellbeing, 
which ranges from 0 to 24. The SF-36 instrument 
includes eight domains of physical functioning, social 
functioning, vitality, role limitations (physical), role 
limitations (emotional), mental health, general health, 
and bodily pain, and each domain score ranges from 0 to 
100. SF-12 consists of a physical composite score (PCS) 
and mental composite score (MCS), each of which have 
six items, and scores range from 0 to 100. For all three 
instruments, a higher score represents better quality of 
life. All questionnaires were scored in accordance with 
the recommended scoring manuals.10–14 Not all 
respondents answered all questions; all available data 
points were used in analyses.
Separate QoL analyses were planned after 2 and 5 years 
of follow-up, and this report describes PROs up to 
2 years. 
Outcomes
The primary endpoint was the single item “Overall how 
much of a problem have your bowels been for you during 
the last 4 weeks” (overall bowel bother). This question 
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was chosen because it gives a good overall measure of 
bowel-associated morbidity and is common to both the 
UCLA-PCI and EPIC instruments, so was reported by all 
patients. The main secondary endpoints were overall 
urinary bother and overall sexual bother. Additional 
secondary endpoints were individual bowel, urinary, and 
sexual items and domain scores assessed within EPIC 
and UCLA-PCI and the general health-related QoL 
domain scores in FACT-P, SF-36, and SF-12.
Statistical analysis
For all endpoints, the control group was compared with 
each of the experimental groups, as per the statistical 
analysis plan of the main trial. Formal statistical tests were 
done at 24 months. After this analysis, a post-hoc pragmatic 
comparison was done between the 60 Gy and 57 Gy 
experimental schedules to support clinical management 
choices if both hypofractionated schedules were shown to 
be non-inferior to standard fractionation for disease 
control. With 443 patients per experimental group, this 
substudy would have 80% power and 2·5% two-sided 
signiﬁ cance to detect changes in the proportion of patients 
with overall bowel bother scores as follows: from 65% in 
the standard fractionation group to 60% in an experimental 
hypofractionation group for scores of 1 (no bother), from 
22% to 20% for scores of 2 (very small bother), from 7% to 
10% for scores of 3 (small bother), and from 6% to 10% for 
scores of 4 or 5 (moderate or severe bother). Because the 
trial was not originally powered for QoL analyses, these 
calculations were done retrospectively, but before any 
analysis occurred. Power calculations were based on 
comparisons of two independent groups of ordered 
categorical data, with constant odds ratios computed 
across all categories, and assumed complete data would be 
available for 70% of patients (1330 individuals) at 2 years. 
A signiﬁ cance level of 0·001 and 99% conﬁ dence intervals 
686 with data from at least one assessment
 327 at trial entry
 552 pre-radiotherapy
 477 at 24 months 
 425 at baseline* and 24 months
3216 patients entered trial
2100 patients entered QoL study
696 randomly allocated 74 Gy in 
 37 fractions over 7·4 weeks
698 randomly allocated 60 Gy in 
 20 fractions over 4·0 weeks  
706 randomly allocated 57 Gy in 
 19 fractions over 3·8 weeks
676 with data from at least one assessment
 307 at trial entry
 550 pre-radiotherapy
 471 at 24 months
 425 at baseline* and 24 months
692 with data from at least one assessment
 318 at trial entry
 557 pre-radiotherapy
 496 at 24 months
 455 at baseline* and 24 months
Patients with valid† assessment for fixed 
timepoint analysis
256 at trial entry
505 pre-radiotherapy
431 at 10 weeks 
514 at 6 months
474 at 12 months
435 at 18 months
417 at 24 months
Patients with valid† assessment for fixed 
timepoint analysis
250 at trial entry
509 pre-radiotherapy
444 at 10 weeks
504 at 6 months
497 at 12 months
440 at 18 months
411 at 24 months
Patients with valid† assessment for fixed 
timepoint analysis
238 at trial entry
517 pre-radiotherapy
442 at 10 weeks
521 at 6 months
503 at 12 months
457 at 18 months
444 at 24 months
1116 not entered into QoL study
 1080 QoL study closed before main trial
  36 declined entry
20 with no QoL data
 2 withdrew from trial
 2 withdrew from QoL study
 2 ineligible for trial 
 5 data only after 2 years
 2 died
 3 lost to follow-up
 4 not known
12 with no QoL data
 2 withdrew from QoL study
 2 ineligible for trial 
 2 data only after 2 years
 2 lost to follow-up
 4 not known
14 with no QoL data
 1 withdrew from QoL study
 2 ineligible for trial 
 5 data only after 2 years
 1 patient frailty
 5 not known
Figure 1: Quality-of-life study proﬁ le
*Trial entry or pre-radiotherapy if patients were receiving endocrine therapy at trial entry. †Patients were excluded from the ﬁ xed timepoint analyses if their QoL 
assessments were dated outside prespeciﬁ ed acceptable time intervals: after 1 month of endocrine treatment or after randomisation for baseline; before 3 months or 
after 1 week of starting radiotherapy for pre-radiotherapy; outside 2 weeks from the expected date of completion for 10 weeks; and outside of 3 months from the 
expected date of completion for later timepoints. QoL=quality of life.
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were used, guided by a Bonferroni adjustment, to make 
some allowance for multiple testing.
We did cross-sectional, time-to-event, and change-from-
baseline analyses. Cross-sectional analysis was done at 
each timepoint, with formal comparisons between 
treatment groups at 24 months via the χ² test for trend 
and the Mann-Whitney U test. We combined moderate 
and severe events for the formal comparisons because of 
the small number of severe events. We did time-to-event 
analysis using Kaplan-Meier methods and the log-rank 
test to assess time to small or worse, and moderate or 
worse events for individual items. This analysis aimed to 
detect diﬀ erences in late radiation toxic eﬀ ects between 
treatment groups and therefore did not include the 
10-week post-radiotherapy assessment, which assessed 
acute symptoms. Time-to-event was therefore measured 
from the start of radiotherapy to the QoL assessments at 
6, 12, 18, or 24 months. Patients who reached the relevant 
endpoint at trial entry or pre-radiotherapy were excluded 
from that speciﬁ c time-to-event analysis.
We assessed change from baseline (post-radiotherapy 
score minus baseline score) to account for diﬀ erences in 
pre-existing comorbidity between groups. For bowel and 
urinary items and domain scores, we used the pre-
radiotherapy score as a surrogate baseline score unless it 
was missing, in which case the baseline score was used. 
We used this surrogate to maximise numbers. To assess 
the sensitivity of the results to this assumption, analyses 
were repeated using baseline data only. For sexual 
endpoints, only the baseline score at trial entry was used. 
A sensitivity analysis was also done to conﬁ rm the 
robustness of including the baseline assessments of 
patients receiving less than 1 month of endocrine 
treatment which involved repeating analyses using 
baseline assessments of patients receiving no endocrine 
therapy beforehand.
We modelled the odds of any speciﬁ c change from 
baseline or pre-radiotherapy to 24 months using ordinal 
logistic regression after checking the validity of the 
proportional odds assumption.15 Odds ratios less than one 
favour the relevant experimental group. For the ordinal 
logistic regression models, the dependent variable is the 
post-radiotherapy score minus the baseline or pre-
radiotherapy score, taking values of –4, –3, –2, –1, 0, 1, 2, 3, 
or 4, where negative numbers represent an improvement 
in QoL and positive numbers represent worsening QoL. 
We used ANCOVA modelling to assess change from 
baseline for continuous variables such as domain scores, 
adjusting for baseline or pre-radiotherapy score as 
indicated above. We assessed the normality assumption of 
the ANCOVA model visually via histograms and we did 
not deem formal tests to be necessary. Patients were 
excluded from the ﬁ xed timepoint analyses if their QoL 
assessments were dated outside prespeciﬁ ed acceptable 
time intervals, as outlined in ﬁ gure 1.
No imputation of missing PRO data was done. For 
missing individual items, domain scores were only 
calculated if suﬃ  cient items were completed in 
accordance with the relevant scoring manual. For absent 
whole instruments, the eﬀ ect of these missing data was 
assessed by comparison of the baseline characteristics of 
patients present in the analysis versus, ﬁ rst, those who 
consented but were missing entirely, and second, those 
who consented but were missing at 24 months, when 
formal statistical testing was done.
Analysis was on an intention-to-treat basis and all 
analyses were done with Stata version 13.1. The CHHiP 
trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN97182923.
Role of the funding source
The funders provided peer-reviewed approval for the 
study concept but had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. AW, HM, CG, and EH had access to all the 
raw data. The lead and corresponding authors had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
74 Gy in 37 fractions 
(n=676)
60 Gy in 20 fractions 
(n=686)
57 Gy in 19 fractions 
(n=692)
Age (years) 69 (65–73) 69 (64–73) 68 (64–73)
T stage
T1a/1b/1c/1x 224 (33%) 273 (40%) 252 (36%)
T2a/b/c/x 393 (58%) 355 (52%) 368 (53%)
T3a/x 59 (9%) 57 (8%) 71 (10%)
Unknown 0 (0%) 1 (<1%) 1 (<1%)
Gleason score
≤6 248 (37%) 252 (37%) 233 (34%)
7 406 (60%) 413 (60%) 432 (62%)
8 22 (3%) 21 (3%) 27 (4%)
Prostate-speciﬁ c antigen (ng/mL)
Median (IQR) 10·4 (7·3–14·6) 11·0 (7·8–15·5) 10·4 (7·2–14·5)
Mean (SD) 11·3 (5·3) 11·9 (5·8) 11·3 (5·4)
0·00–4·99 44 (7%) 51 (7%) 46 (7%)
5·00–9·99 267 (39%) 249 (36%) 274 (40%)
10·00–19·90 319 (47%) 327 (48%) 321 (46%)
20·00–40·00 46 (7%) 59 (9%) 49 (7%)
Unknown 0 (0%) 0 (0%) 2 (<1%)
NCCN risk group
Low 104 (15%) 113 (16%) 109 (16%)
Intermediate 496 (73%) 498 (73%) 496 (72%)
High 76 (11%) 75 (11%) 87 (13%)
Diabetes
Yes 74 (11%) 65 (9%) 77 (11%)
No 599 (89%) 619 (90%) 606 (88%)
Unknown 3 (<1%) 2 (<1%) 9 (1%)
Hypertension
Yes 248 (37%) 281 (41%) 273 (39%)
No 423 (63%) 403 (59%) 414 (60%)
Unknown 5 (<1%) 2 (<1%) 5 (<1%)
(Table 1 continues on next page)
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Results
Between Oct 18, 2002, and Nov 1, 2009, 2100 patients 
were recruited from 57 centres in the UK (ﬁ gure 1 and 
appendix p 14) into the QoL substudy of the CHHiP trial; 
subsequently, the substudy closed to accrual. 696 patients 
were assigned to the standard 74 Gy schedule, 698 were 
assigned to the 60 Gy schedule, and 706 were assigned to 
the 57 Gy schedule.
Median follow-up was 50·0 months (IQR 38·4–64·2) 
on April 9, 2014, which was the most recent follow-up 
measurement of all data collected before the QoL data 
snapshot for this analysis in September, 2014. At trial 
entry, 700 (86%) of the 812 eligible patients who had not 
started endocrine treatment plus 252 patients who had 
started endocrine treatment returned questionnaires. 
Questionnaires were returned by 1659 (79%) patients 
pre-radiotherapy, 1470 (70%) patients at 10 weeks, 
1597 (76%) patients at 6 months, 1551 (74%) patients at 
12 months, 1456 (69%) patients at 18 months, and 
1444 (69%) patients at 24 months.
Baseline characteristics of patients were balanced 
between treatment groups except for an imbalance in 
T stage between the 74 Gy and 60 Gy groups (table 1). 
1490 (71%) patients had intermediate NCCN risk 
disease.16
For 46 patients reported to have consented to enter the 
substudy, no QoL assessments were received by the 
ICR-CTSU. Baseline characteristics for these patients 
were not signiﬁ cantly diﬀ erent from those of patients 
present in the analysis (appendix p 1). 828 (39%) patients 
who had consented to participate in the substudy had no 
QoL assessments available at 24 months. The only 
signiﬁ cant diﬀ erence in baseline characteristics between 
groups with and without 24-month PRO data was that 
patients with missing questionnaires were more likely to 
have high NCCN risk disease at trial entry than were 
patients who provided data (appendix p 2). Of patients 
with data from at least one QoL assessment, 665 (98%) of 
676 in the 74 Gy treatment group, 674 (98%) of 686 in the 
60 Gy treatment group, and 677 (98%) of 692 in the 57 Gy 
treatment group received endocrine therapy. 
The incidence of overall bowel bother was low (ﬁ gure 2, 
appendix p 3). At 24 months post-radiotherapy, we 
recorded no overall bowel bother for 269 (66%) of 
410 men treated with 74 Gy, 266 (65%) of 411 men treated 
with 60 Gy, and 282 (65%) of 437 men treated with 57 Gy; 
very small bother for 92 (22%), 91 (22%), and 93 (21%) 
men; small bother for 26 (6%), 28 (7%), and 38 (9%) men; 
moderate bother for 19 (5%), 23 (6%), 21 (5%) men; and 
severe bother for four (<1%), three (<1%), and three (<1%) 
men, respectively. Cross-sectional analysis at 24 months 
showed no signiﬁ cant diﬀ erences in overall bowel bother 
between the treatment groups (74 Gy vs 60 Gy, ptrend=0·64; 
74 Gy vs 57 Gy, ptrend=0·59; appendix p 3). 
A temporary increase in any bowel bother was seen at 
10 weeks (a change from 413 [27%] of 1509 patients pre-
radiotherapy to 745 [57%] of 1309 patients at 10 weeks). At 
6 months, any bowel bother had decreased (581 [38%] of 
1519 patients), and remained around this level to 
24 months, when any overall bowel bother was reported 
by 441 (35%) of 1258 patients. A sensitivity analysis 
showed that using pre-radiotherapy scores as a surrogate 
for baseline scores at trial entry for some patients was 
valid (appendix p 11–12). Because 252 men completed 
baseline questionnaires after starting endocrine 
treatment, a sensitivity analysis was done, which 
conﬁ rmed the robustness of including patients receiving 
less than 1 month of endocrine treatment at baseline 
(appendix p 13).
The pattern in overall urinary bother was similar to that 
for overall bowel bother (ﬁ gure 2, appendix p 4) and cross-
sectional analysis at 24 months showed no signiﬁ cant 
diﬀ erences in overall urinary bother between treatment 
groups (appendix p 4). The baseline incidence of overall 
sexual bother was higher than that for bowel or urinary 
bother, with 412 (57%) of 719 patients having any bother at 
baseline, which increased to 975 (68%) of 1440 patients 
pre-radiotherapy and improved from 6 months to 
24 months (ﬁ gure 2, appendix p 4). There were no 
signiﬁ cant diﬀ erences between treatment groups
At 24 months, we noted no signiﬁ cant diﬀ erences 
between treatment groups for all other individual 
74 Gy in 37 fractions 
(n=676)
60 Gy in 20 fractions 
(n=686)
57 Gy in 19 fractions 
(n=692)
(Continued from previous page)
Inﬂ ammatory bowel or diverticular disease
Yes 25 (4%) 21 (3%) 27 (4%)
No 646 (96%) 663 (97%) 659 (95%)
Unknown 5 (<1%) 2 (<1%) 6 (1%)
Previous pelvic surgery
Yes 55 (8%) 51 (7%) 53 (8%)
No 616 (91%) 633 (92%) 632 (91%)
Unknown 5 (<1%) 2 (<1%) 7 (1%)
Symptomatic haemorrhoids in past 12 months
Yes 39 (6%) 50 (7%) 52 (8%)
No 620 (92%) 617 (90%) 623 (90%)
Unknown 17 (3%) 19 (3%) 17 (2%)
Previous transurethral resection of the prostate
Yes 55 (8%) 61 (9%) 62 (9%)
No 606 (90%) 615 (90%) 617 (89%)
Unknown 15 (2%) 10 (1%) 13 (2%)
Hormone treatment duration 
(days)* 
140 (113–169) 132 (102–165) 127 (102–157)
Time from androgen suppression 
to start of radiotherapy (days)
116 (103–138) 118 (103–138) 115 (103–139)
Time from radiotherapy start to 
end of androgen suppression 
(days)†
16 (–3 to 42) 6 (–6 to 24) 6 (–7 to 23)
Data are n (%) or median (IQR) unless otherwise stated. NCCN=National Comprehensive Cancer Network. *Hormone 
treatment duration was the total duration, including before study entry. †Negative values are from patients 
who stopped androgen suppression before starting radiotherapy. 
Table 1: Baseline characteristics and clinical history 
See Online for appendix
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Figure 2: Overall bowel, urinary, and sexual bother
Data are prevalence of overall bowel bother (A), time to small or worse overall bowel bother (B), prevalence of overall urinary bother (C), time to small or worse overall urinary bother (D), prevalence of 
overall sexual bother (E), and time to small or worse overall sexual bother (F).
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bowel, urinary, and sexual items assessed (appendix 
pp 3–4). Bowel, urinary, and sexual domain scores 
assessed within UCLA-PCI or EPIC QoL instruments 
also showed no diﬀ erence between treatments at 
24 months (table 2).
Time-to-event analysis of small or worse overall bowel, 
urinary, and sexual bother showed no signiﬁ cant 
diﬀ erences between treatment groups for any endpoints 
(ﬁ gure 2). The appendix contains absolute numbers of 
cumulative small or worse and moderate or worse 
events, the prevalence of the relevant bowel, urinary, and 
sexual symptoms before radiotherapy, and the hazard 
ratios for the time-to-event analysis time from start of 
radiotherapy to small or worse and moderate or worse 
events for all individual items in all treatment groups 
(appendix pp 5 and 6). The number of patients reporting 
symptoms that were represented only in EPIC (faecal 
incontinence, rectal bleeding, daily bowel movements, 
dysuria, and haematuria) was considerably lower than 
that for other endpoints, so these analyses were 
underpowered.
Although we saw no signiﬁ cant diﬀ erences between 
treatment groups, the cumulative incidence of some 
symptoms, including faecal incontinence, rectal 
bleeding, and use of urinary pads, was higher in patients 
treated with hypofractionated radiation than in those 
treated with standard fractionation (appendix p 5). 
However, at 24 months, diﬀ erences in the prevalence of 
these symptoms between groups were smaller (appendix 
pp 3–4).
Figure 3 shows change from baseline for UCLA-PCI 
domain scores and EPIC domain summary scores; 
additional EPIC domain scores are shown in the 
appendix (p 10). There were no signiﬁ cant diﬀ erences 
between treatment groups. For all urinary and bowel 
items and domain scores, to maximise numbers, the pre-
radiotherapy score was used as a surrogate baseline score 
unless missing, in which case the baseline score was 
used; exact numbers are: 749 pre-radiotherapy plus 
65 baseline for change in UCLA-PCI bowel function to 
24 months; 146 plus 14 for change in EPIC bowel 
summary to 24 months; 751 plus 64 for change in UCLA-
PCI urinary function to 24 months; and 139 plus 16 for 
change in EPIC urinary summary to 24 months (numbers 
per treatment group shown in appendix p 14). 
Figure 3 also shows change from baseline in scores for 
the individual items of overall bowel bother, overall 
urinary bother, and overall sexual bother; all other 
endpoints are shown in the appendix (p 8). Most patients 
had no change in score from baseline and we noted no 
signiﬁ cant diﬀ erences between treatment groups in 
change from baseline to 24 months for any individual 
items. Compared to the 74 Gy control group, the odds of a 
one-point increase in overall bowel bother were reduced, 
although not signiﬁ cantly, in the 60 Gy treatment group 
(odds ratio [OR] 0·85 [99% CI 0·57–1·26]; p=0·29) and the 
57 Gy treatment group (OR 0·84 [0·57–1·24]; p=0·25). For 
some endpoints, the odds of a patient developing side-
eﬀ ects were slightly increased for the 60 Gy group 
compared with the 57 Gy group, but none of these 
increases were signiﬁ cant (appendix p 8). Again for 
urinary and bowel overall bother items, the pre-
radiotherapy score was used as a surrogate for baseline. 
Exact numbers are 971 pre-radiotherapy plus 85 baseline 
for overall bowel bother; 969 plus 84 for overall urinary 
bother (per treatment group shown in appendix p 14).
We identiﬁ ed no signiﬁ cant diﬀ erences in health-
related QoL domain scores measured by FACT-P, SF-12, 
74 Gy in 37 fractions (n=676) 60 Gy in 20 fractions (n=686) 57 Gy in 19 fractions (n=692) 74 Gy vs 
60 Gy 
p value*
74 Gy vs 
57 Gy 
p value*
60 Gy vs 
57 Gy 
p value*
Number of 
patients with 
data
Median (IQR) Number of 
patients with 
data
Median (IQR) Number of 
patients with 
data
Median (IQR)
Bowel function (UCLA) 312 (46%) 93·8 (82·5–100·0) 310 (45%) 91·8 (79·3–100·0) 331 (48%) 93·8 (81·3–100·0) 0·064 0·77 0·12
Urinary function (UCLA) 311 (46%) 100·0 (81·8–100·0) 313 (46%) 100·0 (81·8–100·0) 334 (48%) 100·0 (83·5–100·0) 0·69 0·47 0·74
Sexual function (UCLA) 307 (45%) 27·1 (4·1–53·1) 300 (44%) 23·4 (7·3–57·3) 321 (46%) 26·0 (7·3–56·3) 0·39 0·33 0·92
Bowel function (EPIC) 95 (14%) 96·4 (89·3–96·4) 94 (14%) 96·4 (89·3–100·0) 100 (14%) 92·9 (85·7–98·2) 0·15 0·51 0·059
Bowel bother (EPIC) 95 (14%) 95·8 (87·5–100·0) 96 (14%) 95·8 (83·3–100·0) 101 (15%) 95·8 (79·2–100·0) 0·54 0·15 0·38
Bowel summary (EPIC) 93 (14%) 94·2 (88·5–98·1) 94 (14%) 94·2 (87·5–100·0) 99 (14%) 94·2 (84·6–98·1) 0·41 0·41 0·15
Urinary function (EPIC) 97 (14%) 100·0 (93·4–100·0) 99 (14%) 100·0 (88·4–100·0) 104 (15%) 100·0 (90·9–100·0) 0·18 0·84 0·11
Urinary bother (EPIC) 89 (13%) 89·3 (79·2–96·4) 95 (14%) 89·3 (78·6–96·4) 102 (15%) 90·5 (75·0–96·4) 0·64 0·72 0·38
Urinary summary (EPIC) 89 (13%) 91·0 (85·4–97·9) 95 (14%) 93·1 (82·7–97·9) 101 (15%) 93·8 (82·7–97·9) 1·00 0·91 0·93
Sexual function (EPIC) 89 (13%) 21·6 (0·0–60·0) 88 (13%) 21·6 (0·0–53·4) 98 (14%) 26·6 (0·0–58·4) 0·78 0·74 0·53
Sexual summary (EPIC) 92 (14%) 28·4 (15·2–62·5) 93 (14%) 23·7 (16·7–58·3) 99 (14%) 27·8 (13·8–61·2) 0·60 0·84 0·74
EPIC-50 was used for bowel and urinary domains and EPIC-26 for sexual domains. UCLA-PCI=University of California, Los Angeles Prostate Cancer Index. EPIC=Expanded Prostate Cancer Index Composite. 
*Mann-Whitney U test.
Table 2: Bowel, urinary, and sexual domain scores at 24 months for UCLA-PCI and EPIC QoL instruments
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and SF-36 between treatment groups at 24 months 
(appendix p 9). For most domains, there was a 
consistent pattern of stable scores across all timepoints, 
including pre-radiotherapy and 10 weeks post-
radiotherapy timepoints. However, for the SF-36 
domains of vitality, physical role functioning, and social 
wellbeing, we noted a reduction of more than 10 points 
between the median domain score at baseline and at 
10 weeks after the start of radiotherapy in all treatment 
groups. By 6 months, median scores had increased to 
within 10 points of the median scores at baseline for all 
three measures.
Discussion
In this QoL substudy of the CHHiP trial, PROs were not 
signiﬁ cantly diﬀ erent between treatment groups for any 
of the endpoints assessed. Both cross-sectional analysis at 
24 months and time-to-event analysis suggest an overall 
pattern of low incidence of bowel and urinary toxic eﬀ ects 
in all treatment groups. The QoL instruments used were 
sensitive to change because acute toxic eﬀ ects were clearly 
distinguished using both individual items and bowel, 
urinary, and sexual domain scores. These acute toxic 
eﬀ ects had a small and short-lived eﬀ ect on general health-
related QoL, especially the SF-36 domains of vitality, 
Figure 3: Change in domain scores and single item overall bother scores from baseline to 24 months
Change in UCLA-PCI bowel function domain score*† (A); change in EPIC bowel summary domain score*† (B); change in overall bowel bother from pre-radiotherapy† to 24 months (C); change in 
UCLA-PCI urinary function domain score*† (D); change in EPIC urinary summary domain score*† (E); change in overall urinary bother from pre-radiotherapy† to 24 months (F); change in UCLA-PCI 
sexual function domain score* (G); change in EPIC sexual summary domain score* (H); and change in overall sexual bother from baseline to 24 months (I). EPIC=Expanded Prostate Cancer Index 
Composite. UCLA-PCI=University of California, Los Angeles Prostate Cancer Index. Error bars are 99% CIs.*Higher domain scores indicate better function. †For all urinary and bowel items and domain 
scores, to maximise numbers, the pre-radiotherapy score was used as a surrogate baseline score unless missing, in which case the baseline score was used.
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physical role functioning, and social wellbeing. Overall, 
changes from baseline to 24 months for urinary, bowel, 
and most general health-related QoL domains (except role 
limitations [physical]), were less than previously reported 
minimally important diﬀ erences derived from 
longitudinal anchor-based methods.17 Although further 
development of toxic eﬀ ects is possible after 2 years, 
recent studies have reported minimal change in late 
radiotherapy side-eﬀ ects after 2 years following external 
beam radiation therapy.18 This suggests that 2 years is an 
appropriate endpoint for initial PRO reporting.
To our knowledge, this is the ﬁ rst large randomised trial 
of hypofractionated radiotherapy that used modern 
radiotherapy techniques to report PROs with follow-up to 
24 months. Aluwini and colleagues19 reported preliminary 
results that included PROs up to 3 months in the HYPRO 
study,19 which included 820 patients. Radiotherapy doses 
were higher in HYPRO (standard fractionation of 
39 fractions of 2 Gy in 8 weeks vs hypofractionation with 
19 fractions of 3·4 Gy in 6·5 weeks) than in CHHiP. 
Combined clinician-reported outcomes and PROs showed 
similar acute genitourinary toxic eﬀ ects between 
treatments, but increased acute gastrointestinal toxic 
eﬀ ects with hypofractionation. A small (124 patients) 
randomised study of moderate hypofractionation (63 Gy in 
20 fractions) versus conventional fractionation (76 Gy in 
38 fractions) reported no diﬀ erence in EPIC scores between 
treatment groups up to 3 months after radiotherapy.20
The PROs in this study are broadly consistent with 
preliminary data for clinician-reported outcomes in the 
CHHiP trial,4 and the clinician-reported outcomes of a 
small (168 patients) phase 3 trial in Italy.21 Results from 
another randomised trial that included 203 patients 
showed a non-signiﬁ cant numerical increase in clinician-
reported late gastrointestinal toxic eﬀ ects with 
hypofractionation.22 However, the radiotherapy dose 
schedules used in these studies21,22 diﬀ er substantially 
from those in CHHiP.
So far, randomised trials21–25 reporting the eﬀ ects of 
hypofractionation versus conventional fractionation have 
reported inconsistent results for side-eﬀ ects and do not 
clearly show a diﬀ erence in the rate of increase of 
genitourinary or gastrointestinal toxic eﬀ ects between 
conventional and hypofractionated radiotherapy 
treatments.26 These ﬁ ndings emphasise the need for 
outcome data from large trials of hypofractionation that 
use modern radiotherapy techniques. Such studies to 
compare hypofractionated radiotherapy with standard 
fractionation, together with the clinician-reported 
outcomes from CHHiP, will help to conﬁ rm whether 
faecal incontinence, rectal bleeding, or use of urinary 
pads are more common at a dose of 3 Gy per fraction.
Findings from a trial of hypofractionation25 that 
included 303 patients raised concerns about increased 
urinary toxic eﬀ ects after hypofractionated treatment in 
patients who had compromised urinary function before 
enrolment, as assessed by clinician-reported LENT and 
RTOG scores. A formal comparison restricted to patients 
with baseline dysfunction has not been done in our 
study, partly because obstructive and irritative symptoms, 
and consequently overall urinary dysfunction, are not 
well represented in the UCLA-PCI instrument. We plan 
to do a formal comparison between groups using 
clinician-reported outcomes from RTOG and LENT 
instruments in a separate study. However urinary co-
morbidity was well balanced between treatment groups 
and change in urinary function from baseline did not 
diﬀ er between fractionation schedules. Furthermore, 
overall urinary bother seems to decrease during the 
2 years after radiotherapy, which is consistent with 
ﬁ ndings from the RT01 dose escalation trial.27 
Comparison of bowel bother and distress assessed 
using the UCLA-PCI instrument in both the 74 Gy group 
of CHHiP and the 74 Gy group of the RT01 trial,27 in 
which conventional radiotherapy planning techniques 
were used, suggests that patients beneﬁ t substantially 
from improved treatment methods that use intensity-
modulated radiotherapy and the dose constraints used in 
CHHiP. In RT01, 27 (9%) of 289 patients reported 
moderate bowel bother and nine (3%) patients reported 
severe bother in the 74 Gy group at 24 months.28 This 
compares with 19 (5%) of 410 patients reporting moderate 
bother and four (<1%) patients reporting severe bother in 
the 74 Gy group in CHHiP at 24 months. Similarly, at 
24 months, 34 (12%) of 288 patients in RT0128 versus 
13 (4%) of 312 patients in CHHiP reported moderate 
bowel distress, and two (<1%) patients in RT0128 versus 
none in CHHiP reported severe bowel distress.
Strengths of our study include the wide age range and 
large number of patients recruited from diﬀ erent parts of 
the UK. The use of diﬀ erent QoL instruments was a 
limitation of the analysis, because it meant that fewer 
patients reported some important radiotherapy-related 
toxic eﬀ ects, including rectal bleeding and faecal 
incontinence, which were only represented in EPIC. 
Additionally, domain scores for UCLA-PCI and EPIC are 
not directly comparable, so separate reporting was 
necessary with smaller numbers than used for the 
primary endpoint. EPIC is now regarded as the QoL 
instrument of choice for localised prostate cancer;29 
however, our trial was planned before it was widely 
available. To our knowledge, minimally clinically 
important diﬀ erences have not been published for 
EPIC-50, but will be a valuable addition when available.
Patients might acclimatise to symptoms over time and 
therefore the most subjective endpoints, such as overall 
bowel, urinary, and sexual bother, might under-represent 
the actual toxicity at later timepoints. However, more 
objective PROs, including rectal bleeding, dysuria, and 
quality of erections showed similar patterns of toxic 
eﬀ ects over time compared with overall bother items, 
suggesting that overall bother gives a reliable 
representation of patient experience. Bother items might 
incorporate a psychosocial component as well as actual 
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functional change, but we believe that overall perception 
of toxic eﬀ ects is a comprehensive and comprehensible 
endpoint in a randomised comparison of PROs.
Patients with missing data at 24 months were more 
likely to be in a higher NCCN risk group than were those 
patients with data present. Biochemical recurrence did 
not exclude patients from the PRO substudy, but patients 
might have been less willing to complete the 
questionnaires after relapse. Both NCCN risk group and 
numbers of patients with missing data did not diﬀ er 
between treatment groups, therefore missing data are 
unlikely to have substantially biased the randomised 
comparisons.
PROs at 5 years will be important to conﬁ rm our 
ﬁ ndings. 5-year outcomes, together with longer-term 
clinician-reported outcomes, will help to elucidate 
whether late emergent diﬀ erences exist between 
treatment groups. 5-year eﬃ  cacy data from the CHHiP 
trial will be available in late 2015. Follow-up from 
complementary randomised studies is ongoing and 
together these will clarify the role of moderately 
hypofractionated radiotherapy treatment for localised 
prostate cancer. Radiotherapy treatments need to balance 
the potential increased eﬃ  cacy of biologically increased 
doses with the risk of increased side-eﬀ ects. So far, our 
results show that the bowel and urinary side-eﬀ ects of 
moderate hypofractionation for prostate cancer delivered 
with modern radiotherapy techniques are low and similar 
to those of standard fractionation.
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